117 related articles for article (PubMed ID: 9137438)
1. Effects of cyclophosphamide and ifosfamide on neuroblastoma cells before and after activation by microsomes.
Meyer T; Wierse G; Weinrebe W; Treuner J; Niethammer D; Bruchelt G
Anticancer Res; 1997; 17(2A):981-6. PubMed ID: 9137438
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.
Chang TK; Yu L; Maurel P; Waxman DJ
Cancer Res; 1997 May; 57(10):1946-54. PubMed ID: 9157990
[TBL] [Abstract][Full Text] [Related]
3. Direct detection of the intracellular formation of carboxyphosphamides using nuclear magnetic resonance spectroscopy.
Boal JH; Ludeman SM; Ho CK; Engel J; Niemeyer U
Arzneimittelforschung; 1994 Jan; 44(1):84-93. PubMed ID: 8135883
[TBL] [Abstract][Full Text] [Related]
4. An overview of cyclophosphamide and ifosfamide pharmacology.
Fleming RA
Pharmacotherapy; 1997; 17(5 Pt 2):146S-154S. PubMed ID: 9322882
[TBL] [Abstract][Full Text] [Related]
5. Mixed function oxidase activities of established human colon carcinoma cell lines in the activation of cyclophosphamide.
Moskwa PS; Vadi H; Drewinko B
Cancer Res; 1985 Nov; 45(11 Pt 1):5447-51. PubMed ID: 4053018
[TBL] [Abstract][Full Text] [Related]
6. New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity.
Storme T; Deroussent A; Mercier L; Prost E; Re M; Munier F; Martens T; Bourget P; Vassal G; Royer J; Paci A
J Pharmacol Exp Ther; 2009 Feb; 328(2):598-609. PubMed ID: 19017849
[TBL] [Abstract][Full Text] [Related]
7. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
Chen CS; Jounaidi Y; Waxman DJ
Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
[TBL] [Abstract][Full Text] [Related]
8. Metabolizing systems in cell culture cytotoxicity tests.
Benford DJ; Reavy HJ; Hubbard SA
Xenobiotica; 1988 Jun; 18(6):649-56. PubMed ID: 3420943
[TBL] [Abstract][Full Text] [Related]
9. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of L-cycloserine against human neuroblastoma and medulloblastoma cells is associated with the suppression of ganglioside expression.
Cinatl J; Cinatl J; Kotchetkov R; Pouckova P; Vogel JU; Rabenau H; Michaelis M; Kornhuber B
Anticancer Res; 1999; 19(6B):5349-54. PubMed ID: 10697560
[TBL] [Abstract][Full Text] [Related]
11. Release of a votile factor from solutions of oxazaphosphorines which damage normal and malignant cells.
Blomgren H; Hallström M
Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):391-7. PubMed ID: 2747340
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo.
Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T
Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury.
Kachel DL; Martin WJ
J Pharmacol Exp Ther; 1994 Jan; 268(1):42-6. PubMed ID: 8301583
[TBL] [Abstract][Full Text] [Related]
14. Studies on the in vivo formation of acrolein: 3-hydroxy-propylmercapturic acid as an index of cyclophosphamide (NSC-26271) activation.
Alarcon RA
Cancer Treat Rep; 1976 Apr; 60(4):327-35. PubMed ID: 1277208
[TBL] [Abstract][Full Text] [Related]
15. Effects of retinoic acid on proliferation, apoptosis, cytotoxicity, migration, and invasion of neuroblastoma cells.
Voigt A; Zintl F
Med Pediatr Oncol; 2003 Apr; 40(4):205-13. PubMed ID: 12555246
[TBL] [Abstract][Full Text] [Related]
16. Evidence for peroxidase-mediated metabolism of cyclophosphamide.
Kanekal S; Kehrer JP
Drug Metab Dispos; 1993; 21(1):37-42. PubMed ID: 8095224
[TBL] [Abstract][Full Text] [Related]
17. [Interaction of the three alkylating drugs, cyclophosphamide, ifosfamide and trofosfamide, with DNA and DNA-constituents in vitro (author's transl)].
Lindemann H; Harbers E
Arzneimittelforschung; 1980; 30(12):2075-80. PubMed ID: 7194064
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
Yule SM; Price L; Pearson AD; Boddy AV
Clin Cancer Res; 1997 Nov; 3(11):1985-92. PubMed ID: 9815588
[TBL] [Abstract][Full Text] [Related]
19. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Jounaidi Y; Hecht JE; Waxman DJ
Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro-in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue.
Kuperman AV; Kalgutkar AS; Marfat A; Chambers RJ; Liston TE
Drug Metab Dispos; 2001 Nov; 29(11):1403-9. PubMed ID: 11602515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
